萬邦德(002082.SZ):收到鹽酸溴已新片聯合標準治療/標準治療對於新冠病毒肺炎疑似及輕型患者的療效及安全性評價的總結報告
格隆匯3月20日丨萬邦德(002082.SZ)公佈,近日,萬邦德製藥收到温州醫科大學附屬第二醫院出具的《鹽酸溴已新片聯合標準治療/標準治療對於新型冠狀病毒肺炎疑似及輕型患者的療效及安全性的評價》的總結報告,此次研究項目原計劃納入60例確診或疑似新型冠狀病毒感染的肺炎患者(“受試者”),計劃用藥治療14天。由於國內疫情迅速得到控制,受試者獲取不及預期,實際共篩選23名受試者,篩選合格並隨機入組受試者18例(試驗組12例,對照組6例),其中:9例受試者(試驗組8例,對照組1例)治療不足14天已治癒出院,按方案規定提前結束治療,其餘9例受試者(試驗組4例,對照組5例)按方案規定治療滿14天。研究結論顯示:“由於當前樣本量較少,兩組各指標均無統計學差異。數值上提示,試驗組(鹽酸溴己新片+標準治療組)的需吸氧天數更短、需吸氧比例更少,不良事件肝損發生率較小,有待較大樣本量的研究確證。”
萬邦德製藥將根據上述總結報告的研究結論,結合目前國內外疫情形勢的發展,積極與國內外研究機構溝通,推進後續研究工作的可行性分析,由於此次研究項目的後續推進工作尚存在不確定性,敬請廣大投資者謹慎決策,注意投資風險。截止公告披露日,此次研究項目尚未對公司經營業績產生重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.